Expertise in
52
conditions

Dr. Steven R. Schuster

Hematology
Poudre Valley Health Care Inc.
2121 E Harmony Rd Unit 170, 
Fort Collins, CO 
Accepting New Patients
Offers Telehealth
Expertise in
52
conditions
Poudre Valley Health Care Inc.
2121 E Harmony Rd Unit 170, 
Fort Collins, CO 

Overview

Steven Schuster is a Hematologist practicing medicine in Fort Collins, Colorado.

Dr. Schuster is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL).

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 27 clinical trials. Dr. Schuster is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WY

Hospital Affiliations

Sidney Regional Medical Center
Poudre Valley Hospital
Ivinson Memorial Hospital
Uchealth Greeley Hospital
Medical Center Of The Rockies

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Poudre Valley Health Care Inc.
2121 E Harmony Rd Unit 170, Fort Collins, CO 80528

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2026
Intervention Type: Drug
Study Drugs: Cabozantinib, Nivolumab
Study Phase: Phase 2
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
View 9 Less Clinical Trials

15 Total Publications

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.
Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.
Journal: Future oncology (London, England)
Published: July 06, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (52.7 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manali Kamdar is a Hematologist practicing medicine in Aurora, Colorado. Dr. Kamdar is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kamdar is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

University Of Colorado Hospital

12605 E 16th Ave, 
Aurora, CO 
 (52.7 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Pollyea is a Hematologist practicing medicine in Aurora, Colorado. Dr. Pollyea is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Pollyea is currently accepting new patients.

Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (52.8 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rajeev Vibhakar is a Hematologist and an Oncologist practicing medicine in Aurora, Colorado. Dr. Vibhakar is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Gliomatosis Cerebri. Dr. Vibhakar is currently accepting new patients.

Frequently Asked Questions about Dr. Steven R. Schuster

How do I make an appointment with Dr. Steven R. Schuster?

You can book an appointment with Dr. Steven R. Schuster by calling their office at 970-493-6337. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven R. Schuster a top-rated expert for Classical Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven R. Schuster is classified as an Distinguished expert for Classical Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven R. Schuster specialize in?

While Dr. Steven R. Schuster is a Hematology, they have specific expertise in Classical Hodgkin Lymphoma, Hodgkin Lymphoma, and Richter Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Steven R. Schuster participate in research or clinical trials?

Yes. Dr. Steven R. Schuster has published 15 articles and abstracts on conditions like Classical Hodgkin Lymphoma. You can view a list of Dr. Steven R. Schuster's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Steven R. Schuster accept my insurance?

Dr. Steven R. Schuster accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 970-493-6337 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schuster's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 35 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile